Page 32«..1020..31323334..4050..»

Category Archives: Hormone Replacement Therapy

BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine – PRNewswire

Posted: September 20, 2020 at 4:58 pm

ROCKLAND, Mass. and NEW YORK, Sept. 18, 2020 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. (NYSE: PFE) today announced the publication of detailed results from the Phase III JAVELIN Bladder 100 study online ahead of print in The New England Journal of Medicine. These results were published simultaneously with additional analyses being presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 and describe the efficacy of BAVENCIO(avelumab) as a first-line maintenance treatment across various subgroups of patients with locally advanced or metastatic urothelial carcinoma (UC) and highlight exploratory biomarkers as well as patient-reported outcomes. In June, the US Food and Drug Administration (FDA) approved BAVENCIO for the maintenance treatment of patients with locally advanced or metastatic UC that has not progressed with first-line platinum-containing chemotherapy based on the JAVELIN Bladder 100 results.

In the JAVELIN Bladder 100 study, BAVENCIO plus best supportive care (BSC) significantly extended overall survival (OS) compared with BSC alone in the two primary populations of all randomized patients and patients whose tumors were PD-L1+, and significantly more patients who received BAVENCIO as first-line maintenance were alive at one year.1 The clinical benefits of BAVENCIO were seen across a range of patient populations.1,2

"These data, which supported the recent FDA approval and updates to NCCN and ESMO guidelines, establish that BAVENCIO first-line maintenance treatment could fundamentally change clinical practice for the treatment of patients with locally advanced or metastatic urothelial carcinoma," said Thomas Powles, MBBS, MRCP, MD, Professor of Genitourinary Oncology, Lead for Solid Tumour Research at Barts Cancer Institute, Queen Mary University of London, and Director of Barts Cancer Centre, London, UK. "It is notable that the longer overall survival with BAVENCIO maintenance therapy was observed across all pre-specified subgroups examined and that this prolonged overall survival was gained without a detrimental impact on patients' quality of life."

Primary AnalysisIn the JAVELIN Bladder 100 study, OS was significantly longer with BAVENCIO plus BSC compared to BSC alone in the primary population of all randomized patients (n=700) whose disease had not progressed on first-line platinum-containing chemotherapy:

In the other primary population of patients with PD-L1+ tumors (n=358):

All endpoints were measured from the time of randomization, after completion of four to six cycles of chemotherapy.

Subgroup AnalysisResults of an exploratory subgroup analysis show that consistent results were observed with the JAVELIN Bladder regimen of BAVENCIO first-line maintenance across pre-specified subgroups, including best response to first-line chemotherapy, type of chemotherapy regimen, site of baseline metastasis, and other baseline factors.1 In particular, hazard ratios for OS based on response to first-line chemotherapy were as follows:

With regard to first-line chemotherapy regimen, hazard ratios were as follows:

Further detail from the subgroup analysis were presented in an on-demand mini oral session at the meeting (Presentation #704MO). Additional data evaluating the association between clinical outcomes and exploratory biomarkers will be presented in the Proffered Paper 1 - GU, non prostate session on Saturday, September 19 (Presentation #699O), and patient-reported outcomes are featured in an on-demand e-poster display (Presentation #745P).

Safety No new safety signals were identified in the JAVELIN Bladder 100 study, and the safety profile was consistent with previous studies of BAVENCIO monotherapy.1 Treatment-related adverse events of grade 3 or higher occurred in 57 patients (16.6%) treated with BAVENCIO plus BSC; no grade 3 or higher treatment-related events occurred in the control arm.1 No grade 4 or fatal immune-related adverse events occurred.1 Investigators attributed two patient deaths in the BAVENCIO plus BSC arm (0.6%), due to sepsis and ischemic stroke, to study treatment toxicity.1

About JAVELIN Bladder 100JAVELIN Bladder 100 (NCT02603432) is a Phase III, multicenter, multinational, randomized, open-label, parallel-arm study investigating first-line maintenance treatment with BAVENCIO plus BSC versus BSC alone in patients with locally advanced or metastatic UC. The primary endpoint was OS in the two primary populations of all patients and patients with PD-L1+ tumors defined by the Ventana SP263 assay. Secondary endpoints included progression-free survival, anti-tumor activity, safety, pharmacokinetics, immunogenicity, predictive biomarkers and patient-reported outcomes in the co-primary populations. All primary and secondary endpoints are measured from the time of randomization.

About Urothelial Carcinoma Bladder cancer is the tenth most common cancer worldwide.4 In 2018, there were over half a million new cases of bladder cancer diagnosed, with around 200,000 deaths from the disease globally.4 In the US, an estimated 80,470 cases of bladder cancer were diagnosed in 2019, with around 12,500 locally advanced or metastatic cases presented annually.5,6 UC, which accounts for about 90% of all bladder cancers,7 becomes harder to treat as it advances, spreading through the layers of the bladder wall.8 Only 25% to 55% of patients receive any second-line therapy after first-line chemotherapy.9-15 In the US and EU5 markets, approximately 40% to 50% of patients receive an immune checkpoint inhibitor in second-line therapy.3 For patients with advanced UC, the five-year survival rate is 5%.5

About BAVENCIO (avelumab)BAVENCIO is a human anti-programmed death ligand-1 (PD-L1) antibody. BAVENCIO has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, BAVENCIO has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models.16-18 In November 2014, Merck KGaA, Darmstadt, Germany and Pfizer announced a strategic alliance to co-develop and co-commercialize BAVENCIO.

BAVENCIO Approved IndicationsBAVENCIO (avelumab) is indicated in the US for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy. BAVENCIO is also indicated for the treatment of patients with locally advanced or metastatic UC who have disease progression during or following platinum-containing chemotherapy, or have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

BAVENCIO in combination with axitinib is indicated in the US for the first-line treatment of patients with advanced renal cell carcinoma (RCC).

In the US, the FDA granted accelerated approval for BAVENCIO for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC). This indication is approved under accelerated approval based on tumor response rate and duration of response. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trials.

BAVENCIO is currently approved for patients with MCC in 50 countries globally, with the majority of these approvals in a broad indication that is not limited to a specific line of treatment.

BAVENCIO Important Safety Information from the US FDA-Approved Label BAVENCIO can cause immune-mediated pneumonitis, including fatal cases. Monitor patients for signs and symptoms of pneumonitis and evaluate suspected cases with radiographic imaging. Administer corticosteroids for Grade 2 or greater pneumonitis. Withhold BAVENCIO for moderate (Grade 2) and permanently discontinue for severe (Grade 3), life-threatening (Grade 4), or recurrent moderate (Grade 2) pneumonitis. Pneumonitis occurred in 1.2% of patients, including one (0.1%) patient with fatal, one (0.1%) with Grade 4, and five (0.3%) with Grade 3.

BAVENCIO can cause hepatotoxicity and immune-mediated hepatitis, including fatal cases. Monitor patients for abnormal liver tests prior to and periodically during treatment. Administer corticosteroids for Grade 2 or greater hepatitis. Withhold BAVENCIO for moderate (Grade 2) immune-mediated hepatitis until resolution and permanently discontinue for severe (Grade 3) or life-threatening (Grade 4) immune-mediated hepatitis. Immune-mediated hepatitis occurred with BAVENCIO as a single agent in 0.9% of patients, including two (0.1%) patients with fatal, and 11 (0.6%) with Grade 3.

BAVENCIO in combination with axitinib can cause hepatotoxicity with higher than expected frequencies of Grade 3 and 4 alanine aminotransferase (ALT) and aspartate aminotransferase (AST) elevation. Consider more frequent monitoring of liver enzymes as compared to when the drugs are used as monotherapy. Withhold BAVENCIO and axitinib for moderate (Grade 2) hepatotoxicity and permanently discontinue the combination for severe or life-threatening (Grade 3 or 4) hepatotoxicity. Administer corticosteroids as needed. In patients treated with BAVENCIO in combination with axitinib, Grades3 and 4 increased ALT and AST occurred in 9% and 7% of patients, respectively, and immune-mediated hepatitis occurred in 7% of patients, including 4.9% with Grade3 or 4.

BAVENCIO can cause immune-mediated colitis. Monitor patients for signs and symptoms of colitis. Administer corticosteroids for Grade 2 or greater colitis. Withhold BAVENCIO until resolution for moderate or severe (Grade 2 or 3) colitis until resolution. Permanently discontinue for life-threatening (Grade 4) or recurrent (Grade 3) colitis upon reinitiation of BAVENCIO. Immune-mediated colitis occurred in 1.5% of patients, including seven (0.4%) with Grade 3.

BAVENCIO can cause immune-mediated endocrinopathies, including adrenal insufficiency, thyroid disorders, and type 1 diabetes mellitus.

Monitor patients for signs and symptoms of adrenal insufficiency during and after treatment, and administer corticosteroids as appropriate. Withhold BAVENCIO for severe (Grade 3) or life-threatening (Grade 4) adrenal insufficiency. Adrenal insufficiency was reported in 0.5% of patients, including one (0.1%) with Grade 3.

Thyroid disorders can occur at any time during treatment. Monitor patients for changes in thyroid function at the start of treatment, periodically during treatment, and as indicated based on clinical evaluation. Manage hypothyroidism with hormone replacement therapy and control hyperthyroidism with medical management. Withhold BAVENCIO for severe (Grade 3) or life-threatening (Grade 4) thyroid disorders. Thyroid disorders, including hypothyroidism, hyperthyroidism, and thyroiditis, were reported in 6% of patients, including three (0.2%) with Grade 3.

Type 1 diabetes mellitus including diabetic ketoacidosis: Monitor patients for hyperglycemia or other signs and symptoms of diabetes. Withhold BAVENCIO and administer antihyperglycemics or insulin in patients with severe or life-threatening (Grade 3) hyperglycemia, and resume treatment when metabolic control is achieved. Type 1 diabetes mellitus without an alternative etiology occurred in 0.1% of patients, including two cases of Grade 3 hyperglycemia.

BAVENCIO can cause immune-mediated nephritis and renal dysfunction. Monitor patients for elevated serum creatinine prior to and periodically during treatment. Administer corticosteroids for Grade 2 or greater nephritis. Withhold BAVENCIO for moderate (Grade 2) or severe (Grade 3) nephritis until resolution to Grade 1 or lower. Permanently discontinue BAVENCIO for life-threatening (Grade 4) nephritis. Immune-mediated nephritis occurred in 0.1% of patients.

BAVENCIO can result in other severe and fatal immune-mediated adverse reactions involving any organ system during treatment or after treatment discontinuation. For suspected immune-mediated adverse reactions, evaluate to confirm or rule out an immune-mediated adverse reaction and to exclude other causes. Depending on the severity of the adverse reaction, withhold or permanently discontinue BAVENCIO, administer high-dose corticosteroids, and initiate hormone replacement therapy, if appropriate. Resume BAVENCIO when the immune-mediated adverse reaction remains at Grade 1 or lower following a corticosteroid taper. Permanently discontinue BAVENCIO for any severe (Grade 3) immune-mediated adverse reaction that recurs and for any life-threatening (Grade 4) immune-mediated adverse reaction. The following clinically significant immune-mediated adverse reactions occurred in less than 1% of 1738 patients treated with BAVENCIO as a single agent or in 489 patients who received BAVENCIO in combination with axitinib: myocarditis including fatal cases, pancreatitis including fatal cases, myositis, psoriasis, arthritis, exfoliative dermatitis, erythema multiforme, pemphigoid, hypopituitarism, uveitis, Guillain-Barr syndrome, and systemic inflammatory response.

BAVENCIO can cause severe or life-threatening infusion-related reactions. Premedicate patients with an antihistamine and acetaminophen prior to the first 4 infusions. Monitor patients for signs and symptoms of infusion-related reactions, including pyrexia, chills, flushing, hypotension, dyspnea, wheezing, back pain, abdominal pain, and urticaria. Interrupt or slow the rate of infusion for mild (Grade 1) or moderate (Grade 2) infusion-related reactions. Permanently discontinue BAVENCIO for severe (Grade 3) or life-threatening (Grade 4) infusion-related reactions. Infusion-related reactions occurred in 25% of patients, including three (0.2%) patients with Grade 4 and nine (0.5%) with Grade 3.

BAVENCIO in combination with axitinibcan cause major adverse cardiovascular events (MACE) including severe and fatal events. Consider baseline and periodic evaluations of left ventricular ejection fraction. Monitor for signs and symptoms of cardiovascular events. Optimize management of cardiovascular risk factors, such as hypertension, diabetes, or dyslipidemia. Discontinue BAVENCIO and axitinib for Grade 3-4 cardiovascular events. MACEoccurred in 7% of patients with advanced RCC treated with BAVENCIO in combination with axitinib compared to 3.4% treated with sunitinib. These events included death due to cardiac events (1.4%), Grade 3-4 myocardial infarction (2.8%), and Grade 3-4 congestive heart failure (1.8%).

BAVENCIO can cause fetal harm when administered to a pregnant woman. Advise patients of the potential risk to a fetus including the risk of fetal death. Advise females of childbearing potential to use effective contraception during treatment with BAVENCIO and for at least 1 month after the last dose of BAVENCIO. It is not known whether BAVENCIO is excreted in human milk. Advise a lactating woman not to breastfeed during treatment and for at least 1 month after the last dose of BAVENCIO due to the potential for serious adverse reactions in breastfed infants.

The most common adverse reactions (all grades, 20%) in patients with metastatic Merkel cell carcinoma (MCC) were fatigue (50%), musculoskeletal pain (32%), diarrhea (23%), nausea (22%), infusion-related reaction (22%), rash (22%), decreased appetite (20%), and peripheral edema (20%).

Selected treatment-emergent laboratory abnormalities (all grades, 20%) in patients with metastatic MCC were lymphopenia (49%), anemia (35%), increased aspartate aminotransferase (34%), thrombocytopenia (27%), and increased alanine aminotransferase (20%).

A fatal adverse reaction (sepsis) occurred in one (0.3%) patient with locally advanced or metastatic urothelial carcinoma (UC) receiving BAVENCIO plus best supportive care (BSC) as first-line maintenance treatment. In patients with previously treated locally advanced or metastatic UC, fourteen patients (6%) who were treated with BAVENCIO experienced either pneumonitis, respiratory failure, sepsis/urosepsis, cerebrovascular accident, or gastrointestinal adverse events, which led to death.

The most common adverse reactions (all grades, 20%) in patients with locally advanced or metastatic UC receiving BAVENCIO plus BSC (vs BSC alone) as first-line maintenance treatment were fatigue (35% vs 13%), musculoskeletal pain (24% vs 15%), urinary tract infection (20% vs 11%), and rash (20% vs 2.3%). In patients with previously treated locally advanced or metastatic UC receiving BAVENCIO, the most common adverse reactions (all grades, 20%) were fatigue, infusion-related reaction, musculoskeletal pain, nausea, decreased appetite, and urinary tract infection.

Selected laboratory abnormalities (all grades, 20%) in patients with locally advanced or metastatic UC receiving BAVENCIO plus BSC (vs BSC alone) as first-line maintenance treatment were blood triglycerides increased (34% vs 28%), alkaline phosphate increased (30% vs 20%), blood sodium decreased (28% vs 20%), lipase increased (25% vs 16%), aspartate aminotransferase (AST) increased (24% vs 12%), blood potassium increased (24% vs 16%), alanine aminotransferase (ALT) increased (24% vs 12%), blood cholesterol increased (22% vs 16%), serum amylase increased (21% vs 12%), hemoglobin decreased (28% vs 18%), and white blood cell decreased (20% vs 10%).

Fatal adverse reactions occurred in 1.8% of patients with advanced renal cell carcinoma (RCC) receiving BAVENCIO in combination with axitinib. These included sudden cardiac death (1.2%), stroke (0.2%), myocarditis (0.2%), and necrotizing pancreatitis (0.2%).

The most common adverse reactions (all grades, 20%) in patients with advanced RCC receiving BAVENCIO in combination with axitinib (vs sunitinib) were diarrhea (62% vs 48%), fatigue (53% vs 54%), hypertension (50% vs 36%), musculoskeletal pain (40% vs 33%), nausea (34% vs 39%), mucositis (34% vs 35%), palmar-plantar erythrodysesthesia (33% vs 34%), dysphonia (31% vs 3.2%), decreased appetite (26% vs 29%), hypothyroidism (25% vs 14%), rash (25% vs 16%), hepatotoxicity (24% vs 18%), cough (23% vs 19%), dyspnea (23% vs 16%), abdominal pain (22% vs 19%), and headache (21% vs 16%).

Selected laboratory abnormalities (all grades, 20%) worsening from baseline in patients with advanced RCC receiving BAVENCIO in combination with axitinib (vs sunitinib) were blood triglycerides increased (71% vs 48%), blood creatinine increased (62% vs 68%), blood cholesterol increased (57% vs 22%), alanine aminotransferase increased (ALT) (50% vs 46%), aspartate aminotransferase increased (AST) (47% vs 57%), blood sodium decreased (38% vs 37%), lipase increased (37% vs 25%), blood potassium increased (35% vs 28%), platelet count decreased (27% vs 80%), blood bilirubin increased (21% vs 23%), and hemoglobin decreased (21% vs 65%).

Please see full US Prescribing Informationand Medication Guideavailable at http://www.BAVENCIO.com.

About Merck KGaA, Darmstadt, Germany-Pfizer AllianceImmuno-oncology is a top priority for Merck KGaA, Darmstadt, Germany and Pfizer. The global strategic alliance between Merck KGaA, Darmstadt, Germany and Pfizer enables the companies to benefit from each other's strengths and capabilities and further explore the therapeutic potential of BAVENCIO, an anti-PD-L1 antibody initially discovered and developed by Merck KGaA, Darmstadt, Germany. The immuno-oncology alliance is jointly developing and commercializing BAVENCIO. The alliance is focused on developing high-priority international clinical programs to investigate BAVENCIO as a monotherapy as well as combination regimens, and is striving to find new ways to treat cancer.

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group Website. In case you are a resident of the USA or Canada please go to http://www.emdgroup.com/subscribeto register again for your online subscription of this service as our newly introduced geo-targeting requires new links in the email. You may later change your selection or discontinue this service.

About EMD Serono, Inc.EMD Serono - the biopharmaceutical business of Merck KGaA, Darmstadt,Germany, in the U.S. andCanada- is engaged in the discovery, research and development of medicines for patients with difficult to treat diseases. The business is committed to transforming lives by developing and delivering meaningful solutions that help address the therapeutic and support needs of individual patients. Building on a proven legacy and deep expertise in neurology, fertility and endocrinology, EMD Serono is developing potential new oncology and immuno-oncology medicines while continuing to explore potential therapeutic options for diseases such as psoriasis, lupus and MS. Today, the business has approximately 1,500 employees around the country with commercial, clinical and research operations based in the company's home state ofMassachusetts.www.emdserono.com.

About Merck KGaA, Darmstadt, GermanyMerck KGaA, Darmstadt, Germany, a leading science and technology company, operates across healthcare, life science and performance materials. Around 57,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From advancing gene editing technologies and discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices the company is everywhere. In 2019, Merck KGaA, Darmstadt, Germany, generated sales of 16.2 billion in 66 countries.

The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany operate as EMD Serono in healthcare, MilliporeSigma in life science, and EMD Performance Materials. Since its founding 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.

Pfizer Inc.: Breakthroughs that change patients' livesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at http://www.pfizer.com.In addition, to learn more, please visit us on http://www.pfizer.comand follow us on Twitter at @Pfizerand @Pfizer_News, LinkedIn, YouTubeand like us on Facebook at Facebook.com/Pfizer.

Pfizer Disclosure Notice The information contained in this release is as of September 18, 2020. Pfizer assumes no obligation to update forward-looking statementscontained in this release as the result of new information or future events or developments.

This release contains forward-looking information about BAVENCIO (avelumab), including an indication for first-line maintenance therapy for BAVENCIO for the treatment of patients with locally advanced or metastatic urothelial carcinoma, the alliance between Merck KGaA, Darmstadt, Germanyand Pfizer involving BAVENCIO and clinical development plans, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, uncertainties regarding the commercial success of BAVENCIO; the uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement and/or completion dates for our clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; risks associated with interim data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from our clinical studies; whether and whenany drug applications may be filed in any other jurisdictions for BAVENCIO for first-line maintenance therapy for locally advanced or metastatic urothelial carcinoma in any jurisdictions or for any other potential indications for BAVENCIO or combination therapies in any jurisdictions; whether and when regulatory authorities in any jurisdictions where any applications are pending or may be submitted for BAVENCIO or combination therapies, including BAVENCIO for locally advanced or metastatic urothelial carcinoma may approve any such applications, which will depend on myriad factors, including making a determination as to whether the product's benefits outweigh its known risks and determination of the product's efficacy, and, if approved, whether they will be commercially successful; decisions by regulatory authorities impacting labeling, manufacturing processes, safety and/or other matters that could affect the availability or commercial potential of BAVENCIO, including BAVENCIO for locally advanced or metastatic urothelial carcinoma; the impact of COVID-19 on our business, operations and financial results; and competitive developments.

A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at http://www.sec.gov and http://www.pfizer.com.

References

Your Contacts

EMD Serono Inc.

Media

Noelle Piscitelli

+1 781 427 4351

Investor Relations

+49 6151 72-3321

Pfizer Inc., New York, USA

Media

Dervila Keane (EU)

+353 86 2110834

Jessica Smith

+1 646 899 3178

Investor Relations

Ryan Crowe

+1 215 260 0914

SOURCE EMD Serono

https://www.emdserono.com

Original post:
BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine - PRNewswire

Posted in Hormone Replacement Therapy | Comments Off on BAVENCIO Pivotal Phase III JAVELIN Bladder 100 Results Published in The New England Journal of Medicine – PRNewswire

Early menopause puts women at ‘significantly’ higher risk of depression, study finds – TheSpec.com

Posted: September 20, 2020 at 4:58 pm

Women who experience an early menopause are at a significantly higher risk of depression, according to a McMaster University study based on the largest Canadian data sample to date.

Dr. Alison Shea, an assistant professor at McMaster and an obstetrician and gynecologist at St. Josephs Healthcare Hamilton, led the study which was published in Menopause.

The most striking finding was that those who had an early menopause so before age 40 had a significantly higher risk for depression, she said. Theres more than a doubling of depression risk for these women.

The research used baseline data from 13,216 women aged 45 to 64 collected as part of the Canadian Longitudinal Study on Aging.

In North America, the average age a woman experiences menopause is 51.

The main theory behind the higher risk for depression has to do with estrogen levels, said Shea, who is a specialist in menopause and reproduction mental health. Women who are exposed to estrogen longer from an earlier period and a later menopause have a lower risk of depression later in their life.

There could be social factors, too.

Menopause is a loss of reproductive function, Shea said. That loss is profound for many women. She noted that whether women have had their own children before the onset of menopause is also a significant factor for their mental health.

The study also found that women who had an early menopause were also more likely to experience depression if they had low education, low income, no children, lived alone and had little social support.

While some factors such as ovary removal, radiation, chemotherapy and smoking can cause people to experience menopause early, in most cases, the reason for early menopause is unknown, said Shea, noting that it is believed to be related to auto-immune mechanisms.

She noted that the research can help health practitioners identify women at risk of depression for hormone replacement therapy, which she said not all doctors do.

Its astounding how many women I see in my menopause clinic who they had lost their period at 41 and Im not seeing them until 48. They had all those years of not having any hormones, Shea said. Some family doctors are attuned to this, but others are not.

Ideally, women should begin hormone replacement therapy four to six months after a woman stops having her period, but Shea said most women dont get treatment until they reach the average age of menopause. She noted doctors can refer patients to a gynecologist or a menopause specialist if theyre not comfortable prescribing hormones directly.

Women who may not have begun therapy right away should still speak to a gynecologist, Shea said, adding that hormone therapy can begin within 10 years of the onset of menopause.

Loading...Loading...Loading...Loading...Loading...

She noted that without hormone replacement, women are at a higher risk for other diseases, including heart disease and osteoporosis at an earlier age.

The study also found that those who were using hormone therapy had a higher risk for depression, but Shea said the depression was likely attributed to more severe symptoms of menopause, rather than the hormone therapy itself.

We know that the No. 1 reason for hormone therapy is hot flashes, she said. Hot flashes in the menopause time are a very strong risk factor for depression. Its their more severe menopausal symptoms that are driving their depression rather than the hormone therapy.

Go here to see the original:
Early menopause puts women at 'significantly' higher risk of depression, study finds - TheSpec.com

Posted in Hormone Replacement Therapy | Comments Off on Early menopause puts women at ‘significantly’ higher risk of depression, study finds – TheSpec.com

Predictive Analytics in Healthcare Market Growth Rate, Demands, Status and Application Forecast to 2026 – AlgosOnline

Posted: September 20, 2020 at 4:58 pm

An analysis of Predictive Analytics in Healthcare market has been provided in the latest report available at MarketStudyReport.com, that primarily focuses on the market trends, demand spectrum, and future prospects of this industry over the forecast period. Furthermore, the report provides a detailed statistical overview in terms of trends outlining the geographical opportunities and contributions by prominent industry share contenders.

The report on Predictive Analytics in Healthcare market comprises of growth driving factors, opportunities, and challengers this business sphere will face and the projected remuneration. It assesses global developments and market augmentation providing a detailed information for the businesses operating in this industry. The study helps the firms to make informed decisions and understand the expansion dynamics.

Request a sample Report of Predictive Analytics in Healthcare Market at:https://www.marketstudyreport.com/request-a-sample/2830992?utm_source=algosonline.com&utm_medium=SP

The report contains a competitive study of present and past market scenarios to determine growth rate of this industry over the forecast timespan. Besides, it assesses the COVID-19 outbreak impact on this business sphere and infers methodologies that can be advantageous to the major contenders.

Pivotal pointers from the report:

Product arena:

Application scope:

Regional scope:

Ask for Discount on Predictive Analytics in Healthcare Market Report at:https://www.marketstudyreport.com/check-for-discount/2830992?utm_source=algosonline.com&utm_medium=SP

Competitive arena:

Summarizing, the study analyzes the Predictive Analytics in Healthcare market at a granular level by various segmentations, while keeping track of other significant aspects like sales channel & supply chain which consists of specifications about downstream buyers, upstream suppliers, distributors, and raw materials of this industry.

The key questions answered in the report:

For More Details On this Report: https://www.marketstudyreport.com/reports/global-predictive-analytics-in-healthcare-market-size-status-and-forecast-2020-2026

Some of the Major Highlights of TOC covers:

Predictive Analytics in Healthcare Regional Market Analysis

Predictive Analytics in Healthcare Segment Market Analysis (by Type)

Predictive Analytics in Healthcare Segment Market Analysis (by Application)

Predictive Analytics in Healthcare Major Manufacturers Analysis

Related Reports:

1. Global and Japan Bio-identical Hormone Replacement Therapy Market Insights, Forecast to 2026This report categorizes the and Japan Bio-identical Hormone Replacement Therapy market data by manufacturers, region, type and application, also analyzes the market status, market share, growth rate, future trends, market drivers, opportunities and challenges, risks and entry barriers, sales channels, distributors Analysis.Read More: https://www.marketstudyreport.com/reports/global-and-japan-bio-identical-hormone-replacement-therapy-market-insights-forecast-to-2026

2. Global and Japan Preimplantation Genetic Diagnosis Market Size, Status and Forecast 2020-2026and Japan Preimplantation Genetic Diagnosis Market report starts from illustration of Industry Chain structure, and portrays industry condition, at that point investigations advertise size and figure of and Japan Preimplantation Genetic Diagnosis by item, district and application, likewise, this report presents showcase rivalry circumstance among the merchants profile, plus, advertise value examination and esteem chain highlights are canvassed in this report.Read More: https://www.marketstudyreport.com/reports/global-and-japan-preimplantation-genetic-diagnosis-market-size-status-and-forecast-2020-2026

Read More Reports On: https://www.marketwatch.com/press-release/at-83-cagr-tonic-water-market-size-is-expected-to-exhibit-us-8381-million-by-2025-2020-09-16?tesla=y

Read More Reports On: https://www.marketwatch.com/press-release/neurofeedback-market-size-global-industry-analysis-segments-top-key-players-drivers-and-trends-to-2025-2020-09-16?tesla=y

Contact Us:Corporate Sales,Market Study Report LLCPhone: 1-302-273-0910Toll Free: 1-866-764-2150 Email: [emailprotected]

Visit link:
Predictive Analytics in Healthcare Market Growth Rate, Demands, Status and Application Forecast to 2026 - AlgosOnline

Posted in Hormone Replacement Therapy | Comments Off on Predictive Analytics in Healthcare Market Growth Rate, Demands, Status and Application Forecast to 2026 – AlgosOnline

Hormone Replacement Therapy Hrt Market: Forecast Based on COVID 19 Pandemic: Abbott Laboratories, Novartis, Pfizer – Surfacing Magazine

Posted: June 20, 2020 at 2:45 am

Hormone Replacement Therapy Hrt Market Research Report provides customers with a complete analytical study that provides all the details of key players such as company profile, product portfolio, capacity, price, cost and revenue during the forecast period from 2020 to 2027. A Hormone Replacement Therapy Hrt market that includes Future Trends, Current Growth Factors, Meticulous Opinions, Facts, Historical Data and Statistically Supported And Industry-Validated Market Data.

This Hormone Replacement Therapy Hrt market research provides a clear explanation of how this market will make a growth impression during the mentioned period. This study report scanned specific data for specific characteristics such as Type, Size, Application and End User. There are basic segments included in the segmentation analysis that are the result of SWOT analysis and PESTEL analysis.

RequestSample PDF of Hormone Replacement Therapy Hrt Market Report https://www.worldwidemarketreports.com/sample/340769

Abbott Laboratories, Novartis, Pfizer, Mylan Laboratories, Merck & Co., Amgen, Novo Nordisk, Bayer, Eli Lily, Wyeth, Genentech are some of the major organizations dominating the global market.

(*Note: Other Players Can be Added per Request)

Key players in the Hormone Replacement Therapy Hrt market were identified through a second survey, and market share was determined through a first and second survey. All measurement sharing, splitting and analysis were solved using a secondary source and a validated primary source. The Hormone Replacement Therapy Hrt market report starts with a basic overview of the Industry Life Cycle, Definitions, Classifications, Applications, and Industry Chain Structure. The combination of these two factors will help key players meet the market reach and help to understand offered characteristics and customer needs.

The report also makes some important suggestions for the new Hormone Replacement Therapy Hrt market project before evaluating its feasibility. Overall, this report covers Hormone Replacement Therapy Hrt market Sales, Price, Sales, Gross Profit, Historical Growth and Future Prospects. It provides facts related to mergers, acquisitions, partnerships and joint venture activities prevalent in the market.

This report includes market size estimates of value (million US $) and volume (K MT). The top-down and bottom-up approaches are used to estimate and validate the market size of the Hormone Replacement Therapy Hrt market, estimating the size of various other submarkets in the overall market. Major players in the market were identified through secondary studies, and market share was determined through primary and secondary studies. All ratio sharing, splitting and analysis were determined using the secondary source and the identified primary source.

What Hormone Replacement Therapy Hrt Market report offers:

Regions Covered in This Report

Complete knowledge of the Hormone Replacement Therapy Hrt market is based on the latest industry news, opportunities and trends in the expected region. The Hormone Replacement Therapy Hrt market research report provides clear insights into the influential factors expected to change the global market in the near future.

Remarkable Attributes of Hormone Replacement Therapy Hrt Market Report:

About WMR

Worldwide Market Reports is your one-stop repository of detailed and in-depth market research reports compiled by an extensive list of publishers from across the globe. We offer reports across virtually all domains and an exhaustive list of sub-domains under the sun. The in-depth market analysis by some of the most vastly experienced analysts provide our diverse range of clients from across all industries with vital decision making insights to plan and align their market strategies in line with current market trends.

Read the original here:
Hormone Replacement Therapy Hrt Market: Forecast Based on COVID 19 Pandemic: Abbott Laboratories, Novartis, Pfizer - Surfacing Magazine

Posted in Hormone Replacement Therapy | Comments Off on Hormone Replacement Therapy Hrt Market: Forecast Based on COVID 19 Pandemic: Abbott Laboratories, Novartis, Pfizer – Surfacing Magazine

COVID-19 UPDATE: Global Hormone Replacement Therapy Market Future Growth Analysis, Business Demand And Opportunities To 2027 | Allergan, Novo Nordisk…

Posted: June 20, 2020 at 2:45 am

The report showcases the trends that are in vogue, the regions that are growing, the various types of products available and the potential of the industry to provide solutions for a large population. Frequent aspects that are kept into view while formulating this Global Hormone Replacement Therapy Market report include the market type, organization size, availability on-premises, end-users organization type, and the availability in areas such as North America, South America, Europe, Asia-Pacific and Middle East & Africa. The market size, revenue generated from the sales and technologies by various application segments are also evaluated in this Global Hormone Replacement Therapy Market report.

The Global Hormone Replacement Therapy Market report has a lot of features to offer for industry which includes general market conditions, trends, inclinations, key players, opportunities, and geographical analysis. This report emphasizes on changing dynamics, growth-driving factors, restraints, and limitations. It includes a detailed analysis of the Global Hormone Replacement Therapy Market in customer requirements, customer preferences, and the competitive landscape of the overall market. This report employs a SWOT analysis technique for the assessment of the development of the most remarkable market players. Global Hormone Replacement Therapy Market report offers broader perspective of the market place with its comprehensive market insights and analysis

Global hormone replacement therapy marketis expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market is growing with the healthy CAGR in the above-mentioned research forecast period. Emerging markets and huge investment in research and development are the factors responsible for the growth of this market.

Get Sample Report + All Related Graphs & Charts @https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-hormone-replacement-therapy-market

Competitive Landscape and Global Hormone Replacement Therapy Market Share Analysis

Hormone replacement therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies focus related to global hormone replacement therapy market.

The major players covered in the hormone replacement therapy market are Allergan, Novo Nordisk A/S, Sanofi, Abbott, TherapeuticsMD, Inc., Mithra Pharmaceuticals, Pfizer Inc., Novartis AG, Bayer AG, Mylan N.V., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, and Merck KGaA among others.

Global Hormone Replacement Therapy Market Scope and Market Size

Hormone replacement therapy market is segmented on the basis of type, route of administration, end-users and distribution channel.

The factors propelled the growth of hormone replacement therapy market are rise in cases of endocrine diseases across the world and growing awareness toward health as well as rich pipeline is anticipated to drive the hormone replacement therapy market. It is assumed that market for hormone replacement therapy is majorly hampered by scarcity of experts coupled with high treatment cost.

Hormone replacement therapy is a type of hormone therapy that is widely used in the treatment of endocrine diseases. Hormone replacement therapy works either as replacement or replenishing the hormones which are deficient and causes the diseases. The most prominent used of hormone replacement therapy is in the treatment of menopauses symptoms in postmenopausal women.

This hormone replacement therapy market report provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographical expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for anAnalyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.

Grab Your Report at an Impressive 30% Discount! Please click Here @https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-hormone-replacement-therapy-market

Global Hormone Replacement Therapy Market Country Level Analysis

Hormone replacement therapy market is analysed and market size information is provided by country, type, route of administration, end-users and distribution channel as referenced above.

The countries covered in the global hormone replacement therapy market report is U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America. Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe. China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific. Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.

Based on geography, North America holds the major market share for hormone replacement therapy market throughout the coming years. Asia-Pacific emerged as the second growing regional segment in terms of revenue due to the increases cases of cardiovascular diseases and rapidly aging population.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

For More Insights Get Detailed TOC @https://www.databridgemarketresearch.com/toc/?dbmr=global-hormone-replacement-therapy-market

Patient Epidemiology Analysis

Hormone replacement therapy market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

About Data Bridge Market Research:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

[emailprotected]

See original here:
COVID-19 UPDATE: Global Hormone Replacement Therapy Market Future Growth Analysis, Business Demand And Opportunities To 2027 | Allergan, Novo Nordisk...

Posted in Hormone Replacement Therapy | Comments Off on COVID-19 UPDATE: Global Hormone Replacement Therapy Market Future Growth Analysis, Business Demand And Opportunities To 2027 | Allergan, Novo Nordisk…

Impact of COVID-19 on Hormone Replacement Therapy Market Hitting New Highs Between the Forecast Period 2020-2027 | By Leading Players Novartis AG,…

Posted: June 20, 2020 at 2:45 am

Notice:This Content doesnt contains all the Information of the Report please fill the form (via link) and get all interesting information just one click in PDF with latest update with chart and Table of Content

The report offers a systematic presentation of the existing trends, growth opportunities, market dynamics that are expected to shape the growth of the Hormone Replacement Therapy market. The various research methods and tools were involved in the market analysis, to uncover crucial information about the market such as current & future trends, opportunities, business strategies and more, which in turn will aid the business decision-makers to make the right decision in future.

This Report Covers Leading Companies Associated in Worldwide Hormone Replacement Therapy Market: Novartis AG, Abbott Laboratories, Mylan N.V., Merck KgaA, Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Amgen, Inc., and Eli Lilly and Company.

We Do Offer Sample of this report. Kindly go through the follow information in order to access the report.

Note- This report sample includes:

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (Structure Of The Report)

Research methodology adopted by Coherent Market Insights

Request Sample Copy of this Report: https://www.coherentmarketinsights.com/insight/request-sample/2079

The report begins with a brief introduction and market overview of the Hormone Replacement Therapy industry followed by its market scope and size. Next, the report provides an overview of market segmentation such as type, application, and region. The drivers, limitations, and opportunities for the market are also listed along with current trends and policies in the industry.

The key players profiled in this report include: Novartis AG, Abbott Laboratories, Mylan N.V., Merck KgaA, Bayer AG, Pfizer Inc., Novo Nordisk A/S, QuatRx Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Amgen, Inc., and Eli Lilly and Company.

Regions included:

o North America (United States, Canada, and Mexico)

o Europe (Germany, France, UK, Russia, and Italy)

o Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

o South America (Brazil, Argentina, Colombia)

o Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

The PDF Research only provides Table of Contents (ToC), scope of the report and research framework of the report.

Get a PDF Brochure of this Report: https://www.coherentmarketinsights.com/insight/request-pdf/2079

Key Benefits:

o This study gives a detailed analysis of drivers and factors limiting the market expansion of Hormone Replacement Therapy

o The micro-level analysis is conducted based on its product types, end-user applications, and geographies

o Porters five forces model gives an in-depth analysis of buyers and suppliers, threats of new entrants & substitutes and competition amongst the key market players

o By understanding the value chain analysis, the stakeholders can get a clear and detailed picture of this Hormone Replacement Therapy market

The research study can answer the following Key questions:

Table of Contents

Report Overview: It includes the Hormone Replacement Therapy market study scope, players covered, key market segments, market analysis by application, market analysis by type, and other chapters that give an overview of the research study.

Executive Summary: This section of the report gives information about Hormone Replacement Therapy market trends and shares, market size analysis by region and analysis of global market size. Under market size analysis by region, analysis of market share and growth rate by region is provided.

Profiles of International Players: Here, key players of the Hormone Replacement Therapy market are studied on the basis of gross margin, price, revenue, corporate sales, and production. This section gives a business overview of the players and shares their important company details.

Regional Study: All of the regions and countries analyzed in the Hormone Replacement Therapy market report is studied on the basis of market size by application, the market size by product, key players, and market forecast.

Get Offer on Report: https://www.coherentmarketinsights.com/insight/request-discount/2079

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, LATAM, West Europe, MENA Countries, Southeast Asia or Asia Pacific.

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:Coherent Market Insights,1001 4th Ave,#3200 Seattle, WA 98154, U.S.Email: [emailprotected]Phone: US +1-206-701-6702/UK +44-020 8133 4027

Read the original post:
Impact of COVID-19 on Hormone Replacement Therapy Market Hitting New Highs Between the Forecast Period 2020-2027 | By Leading Players Novartis AG,...

Posted in Hormone Replacement Therapy | Comments Off on Impact of COVID-19 on Hormone Replacement Therapy Market Hitting New Highs Between the Forecast Period 2020-2027 | By Leading Players Novartis AG,…

Hormone Replacement Therapy Market Report, History and Forecast 2020-2027, Data Breakdown by Manufacturers, Key Regions, Types and Application -…

Posted: June 20, 2020 at 2:45 am

Global Hormone Replacement Therapy Market

The Global Hormone Replacement Therapy Market report consists of the latest discoveries and technological advancements recorded in the industry, along with an analysis of the factors and their effect on the markets future development. The report focuses on the current businesses and the present-day headways, and the future growth prospects for the Hormone Replacement Therapy market.

This report covers the current COVID-19 effects on the economy. This outbreak has brought along drastic changes in world economic situations. The current scenario of the ever-evolving business sector and present and future appraisal of the effects are covered in the report as well.

Get FREE Sample Copy with TOC of the Report to understand the structure of the complete [emailprotected] https://www.marketexpertz.com/sample-enquiry-form/30801

The global Hormone Replacement Therapy marketreport gives a 360 approach for a holistic understanding of the market scenario. It relies on authentically-sourced information and an industry-wide analysis to predict the future growth of the sector. The study gives a comprehensive assessment of the global Hormone Replacement Therapy industry, along with market segmentation, product types, applications, and value chain.

The study also delivers accurate insights into the market in the forecast duration and other key facts and figures pertaining to the global Hormone Replacement Therapy market.

Leading Hormone Replacement Therapy manufacturers/companies operating at both regional and global levels:

PfizerF. Hoffmann-La RocheMerck SeronoNovartisNovo Nordisk

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Research Objective:

Our panel of trade analysts has taken immense efforts in doing this group action in order to produce relevant and reliable primary & secondary data regarding the global Hormone Replacement Therapy market. Also, the report delivers inputs from the trade consultants that will help the key players in saving their time from the internal analysis. Readers of this report are going to be profited with the inferences delivered in the report. The report gives an in-depth and extensive analysis of the Hormone Replacement Therapy market.

Click here to inquire about customization and available discounts on the [emailprotected] https://www.marketexpertz.com/customization-form/30801

Hormone Replacement Therapy Market has maintained a steady growth rate in the past decade and is predicted to grow at a higher growth rate during the forecast period. The analysis offers an industry-wide evaluation of the market by looking at vital aspects like growth trends, drivers, constraints, opinions of industry experts, facts and figures, historical information, and statistically-backed and trade valid market information to predict the future market growth.

The Global Hormone Replacement Therapy Market is segmented:

In market segmentation by types of Hormone Replacement Therapy, the report covers-

ParenteralTransdermal

This Hormone Replacement Therapy report umbrellas vital elements such as market trends, share, size, and aspects that facilitate the growth of the companies operating in the market to help readers implement profitable strategies to boost the growth of their business. This report also analyses the expansion, market size, key segments, market share, application, key drivers, and restraints.

Get Your Copy at Incredible [emailprotected] https://www.marketexpertz.com/discount-enquiry-form/30801

Hormone Replacement Therapy Market Regional Analysis:

Geographically, the Hormone Replacement Therapy market is segmented across the following regions: North America, Europe, Latin America, Asia Pacific, and Middle East & Africa.

Key Coverage of Report:

Key insights of the report:

Access the Entire Report with TOC, Tables and Figures, and details of Prominent [emailprotected] https://www.marketexpertz.com/industry-overview/hormone-replacement-therapy-market

In conclusion, the Global Hormone Replacement Therapy Market report provides a detailed study of the market by taking into account leading companies, present market status, and historical data to for accurate market estimations, which will serve as an industry-wide database for both the established players and the new entrants in the market.

About Us:Planning to invest in market intelligence products or offerings on the web? Then marketexpertz has just the thing for you reports from over 500 prominent publishers and updates on our collection daily to empower companies and individuals catch-up with the vital insights on industries operating across different geography, trends, share, size and growth rate. Theres more to what we offer to our customers. With marketexpertz you have the choice to tap into the specialized services without any additional charges.

Contact Us:John WatsonHead of Business Development40 Wall St. 28th floor New York CityNY 10005 United StatesDirect Line: +1-800-819-3052Visit our News Site: http://newssucceed.com

See the original post here:
Hormone Replacement Therapy Market Report, History and Forecast 2020-2027, Data Breakdown by Manufacturers, Key Regions, Types and Application -...

Posted in Hormone Replacement Therapy | Comments Off on Hormone Replacement Therapy Market Report, History and Forecast 2020-2027, Data Breakdown by Manufacturers, Key Regions, Types and Application -…

HHS rollback of protections for transgender people could make it harder to provide care – Healthcare IT News

Posted: June 20, 2020 at 2:45 am

On Friday, the U.S. Department of Health and Human Services' Office of Civil Rights moved to roll back protections for transgender people under Section 1557 of the Affordable Care Act, which bans discrimination in healthcare.

The final rule, which goes into effect 60 days after it was announced, reverses Obama-era expansions of sex-based discrimination under Section 1557 to include gender identity or the desire to obtain an abortion.

On Monday, however, the U.S. Supreme Court ruled that sex-based discrimination at the workplace includes discrimination based on gender identity or sexual orientation.

HIMSS20 Digital

Though some advocates believe that this will throw the future of the OCR final rule into question, providers worry that LGBTQ patients, especially trans people, will still avoid sharing information about their identities with clinicians out of fear of discrimination.

This, in turn, could present problems on both an individual and population-wide level.

"Whenever you think that identifying yourself is going tocause problems for you or put you at risk, it creates a culture of fear," said Heather Hitson, SOGI Project Manager at UCLA Health. "It's absolutely what we don't want.

"I'm going tobe cautiously optimistic that we're going to be able to reverse that decision," she added, regarding the final rule. "But for now it's going to weigh on our LGBTQ population's minds: Is this safe for me to share?"

Hitson and her colleague, Dr. Amy Cummings, spoke with Healthcare IT News about their years-long project to include information related to gender identity and sexual orientation in patients' EHRs.

"I was on the health staff at UCLA back before we had the ability to capture any kind of information about LGBTQ status," said Cummings, the informatics chair of the Equitable Care Committee at UCLA. "I remember realizing how difficult it must be to not have your identity aligned with your electronic health record when you're being cared for."

LGBTQ people, especially trans and gender-nonconforming people, have faced rampant discrimination and misunderstanding in clinical settings. As Cummings and Hitson pointed out, including gender identity in a patient's EHR can improve the patient experience, increase patient retention and recruitment and decrease discrimination.

By contrast, studies have shown that failing to be identified by the correct name and pronoun can negatively affect patient satisfaction and quality of care.

Cummings pointed out that if a patient doesn't feel comfortable sharing their identity, it could affect that individual's access to the correct preventive health screenings.

"It makes interpreting labs more difficult," if patients are using hormone replacement therapy, she said. "Both of these issues are serious medical concerns."

From a broader population health perspective, Hitson said, the new HHS rule could also make it more difficult to advance care for the trans community.

"If we're not collecting data and asking these questions" about transgender people and healthcare, "it's going to delay research," Hitson said. "There's limited research in the healthcare community around trans people, and this is going to increase the barrier."

"We were just getting to the point where we were making meaningful conclusions" about LGBTQ care, added Cummings. "Without being able to identify these communities and what they're facing in a rigorously statistical way, it's going to hamper our ability to care for this population."

Hitson noted that healthcare discrimination is particularly harmful for trans people of color, who can experience bothtransphobia and racism. She pointed to the recent murders of black trans women Riah Milton in Ohio and Dominique "RemMie" Fells in Pennsylvania as evidence of the greater dangers trans women of color face.

"People go to their healthcare provider thinking it may be a safe place, but it may not be," said Hitson.

Hitson and Cummings said that providers can demonstrate their solidarity with the LGBTQ community by being visibly supportive of their community through statements on websites and in-office paraphernalia.

Another way, said Hitson, would be to ask questions around sexual orientation and gender identity in a private place, such as a patient portal.

"I think that's a good cue or visual indicator that their doctor is affirming and this is important," she said.

They also urged IT professionals to consider which parts of patient records are shared with other potentially LGBTQ-unfriendly organizations. Their Epic build, for example, decouples name, pronouns, organ inventory and other information from patients' sexual orientation and gender identity.

"People need to think about the impacts of sharing information, even across state lines," said Hitson.

Ultimately, Cummings said, the OCR final rule should not interfere with providers trying to provide patients with the best possible care.

"Protecting LGBTQ patients is always going to be a priority," she said.

Kat Jercich is senior editor of Healthcare IT News.Twitter: @kjercich

Read the original:
HHS rollback of protections for transgender people could make it harder to provide care - Healthcare IT News

Posted in Hormone Replacement Therapy | Comments Off on HHS rollback of protections for transgender people could make it harder to provide care – Healthcare IT News

Hormone Replacement Therapy Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 – Cole of Duty

Posted: June 20, 2020 at 2:45 am

New Jersey, United States,- A detailed research study on Hormone Replacement Therapy Market recently published by Market Research Intellect. This is the latest report, which covers the time COVID-19 impact on the market. Pandemic Coronavirus (COVID-19) has affected every aspect of global life. This has brought some changes in market conditions. Rapidly changing market scenario and the initial assessment and the future of this effect is included in the report. Reports put together a brief analysis of the factors affecting the growth of the current business scenarios in various areas. Important information relating to the size of the industry analysis, sharing, application, and statistics summed up in the report to present the ensemble prediction. In addition, this report includes an accurate competitive analysis of major market players and their strategies during the projection period.

This report includes market size estimates for the value (million USD) and volume (K Units). Both top-down and bottom-up approach has been used to estimate the size of the market and validate the Market of Hormone Replacement Therapy, to estimate the size of the various submarkets more dependent on the overall market. Key players in the market have been identified through secondary research and their market share has been determined through primary and secondary research. All the shares percentage, split, and the damage have been determined using secondary sources and primary sources verified.

Get Sample Copy with TOC of the Report to understand the structure of the complete report @ https://www.marketresearchintellect.com/download-sample/?rid=242433&utm_source=COD&utm_medium=888

Leading Hormone Replacement Therapy manufacturers/companies operating at both regional and global levels:

Hormone Replacement Therapy Market Competitive Landscape & Company Profiles

Competitor analysis is one of the best sections of the report that compares the progress of leading players based on crucial parameters, including market share, new developments, global reach, local competition, price, and production. From the nature of competition to future changes in the vendor landscape, the report provides in-depth analysis of the competition in the Hormone Replacement Therapy market.

Segmental Analysis

Both developed and emerging regions are deeply studied by the authors of the report. The regional analysis section of the report offers a comprehensive analysis of the global Hormone Replacement Therapy market on the basis of region. Each region is exhaustively researched about so that players can use the analysis to tap into unexplored markets and plan powerful strategies to gain a foothold in lucrative markets.

Hormone Replacement Therapy Market, By Product

Hormone Replacement Therapy Market, By Application

Regions Covered in these Report:

Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=242433&utm_source=COD&utm_medium=888

Hormone Replacement Therapy Market Research Methodology

The research methodology adopted for the analysis of the market involves the consolidation of various research considerations such as subject matter expert advice, primary and secondary research. Primary research involves the extraction of information through various aspects such as numerous telephonic interviews, industry experts, questionnaires and in some cases face-to-face interactions. Primary interviews are usually carried out on a continuous basis with industry experts in order to acquire a topical understanding of the market as well as to be able to substantiate the existing analysis of the data.

Subject matter expertise involves the validation of the key research findings that were attained from primary and secondary research. The subject matter experts that are consulted have extensive experience in the market research industry and the specific requirements of the clients are reviewed by the experts to check for completion of the market study. Secondary research used for the Hormone Replacement Therapy market report includes sources such as press releases, company annual reports, and research papers that are related to the industry. Other sources can include government websites, industry magazines and associations for gathering more meticulous data. These multiple channels of research help to find as well as substantiate research findings.

Table of Content

1 Introduction of Hormone Replacement Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Hormone Replacement Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Hormone Replacement Therapy Market, By Deployment Model

5.1 Overview

6 Hormone Replacement Therapy Market, By Solution

6.1 Overview

7 Hormone Replacement Therapy Market, By Vertical

7.1 Overview

8 Hormone Replacement Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Hormone Replacement Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Customized Research Report Using Corporate Email Id @ https://www.marketresearchintellect.com/need-customization/?rid=242433&utm_source=COD&utm_medium=888

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage and more. These reports deliver an in-depth study of the market with industry analysis, market value for regions and countries and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Recycled Glass Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Teleradiology Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Window Sensors Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read more here:
Hormone Replacement Therapy Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 - Cole of Duty

Posted in Hormone Replacement Therapy | Comments Off on Hormone Replacement Therapy Market Analysis, Top Manufacturers, Share, Growth, Statistics, Opportunities and Forecast To 2026 – Cole of Duty

Hormone Replacement Therapy (HRT) MARKET SIZE BY APPLICATION, TYPES, END-USER, REGIONAL ANALYSIS AND FORECAST 2020 TO 2025 – 3rd Watch News

Posted: June 15, 2020 at 10:48 pm

This report additionally covers the effect of COVID-19 on the worldwide market. The pandemic brought about by Coronavirus (COVID-19) has influenced each part of life all inclusive, including the business segment. This has brought along a several changes in economic situations.

Market Research Bazaar has made a brilliant attempt to elaborately and meticulously analyze the global Hormone Replacement Therapy (HRT) market in its latest report. All of the market forecasts presented in the report are authentic and reliable.

The new report offers a powerful combination of latest, in-depth research studies on the Hormone Replacement Therapy (HRT) market. The authors of the report are highly experienced analysts and possess deep market knowledge.

Download Sample Copy of the Report to understand the structure of the complete report (Including Full TOC, Table & Figures): http://marketresearchbazaar.com/requestSample/16848

Major Players Analyzed Under This Report are:

> Abbott LaboratoriesNovartisPfizerMylan LaboratoriesMerck & Co.AmgenNovo NordiskBayerEli LilyWyethGenentech

Hormone Replacement Therapy (HRT) Players/Suppliers Profiles and Sales Data: Company, Company Basic Information, Manufacturing Base and Competitors, Product Category, Application and Specification with Sales, Revenue, Price and Gross Margin, Main Business/Business Overview.

Table Of Content

Market Overview: Scope & Product Overview, Classification of Hormone Replacement Therapy (HRT) by Product Category (Market Size (Sales), Market Share Comparison by Type (Product Category)), Hormone Replacement Therapy (HRT) Market by Application/End Users (Sales (Volume) and Market Share Comparison by Application), Market by Region (Market Size (Value) Comparison by Region, Status and ProspectHormone Replacement Therapy (HRT) Market by Manufacturing Cost Analysis:Key Raw Materials Analysis, Price Trend of Key Raw Materials, Key Suppliers of Raw Materials, Market Concentration Rate of Raw Materials, Proportion of Manufacturing Cost Structure (Raw Materials, Labor Cost), Manufacturing Process Analysis

Key Benefits for Stakeholders

The study provides an in-depth analysis of the Hormone Replacement Therapy (HRT) market size along with the current trends and future estimations to elucidate the imminent investment pockets.Information about key drivers, restraints, and opportunities and their impact analysis on the market size is provided.Porters five forces analysis illustrates the potency of buyers and suppliers operating in the portable gaming industry.The quantitative analysis of the Hormone Replacement Therapy (HRT) industry from 2020 to 2026 is provided to determine the Hormone Replacement Therapy (HRT) market potential.

Hormone Replacement Therapy (HRT) Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020-2026

The research report is broken down into chapters, which are introduced by the executive summary. Its the introductory part of the chapter, which includes details about global market figures, both historical and estimates. The executive summary also provides a brief about the segments and the reasons for the progress or decline during the forecast period. The insightful research report on the Hormone Replacement Therapy (HRT) market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior.

Get Customized Report in your Inbox within 24 hours: http://marketresearchbazaar.com/enquiry/16848

Market Segment Analysis

The research report includes specific segments by Type and by Application. Each type provides information about the production during the forecast period of 2015 to 2026. Application segment also provides consumption during the forecast period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type OralParenteralTransdermalOthers

Segment by Application MenopauseHypothyroidismMale HypogonadismGrowth Hormone DeficiencyOthers

Hormone Replacement Therapy (HRT) Market: Competitive Landscape

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019.

Hormone Replacement Therapy (HRT) Market: Regional Analysis

The report offers in-depth assessment of the growth and other aspects of the Hormone Replacement Therapy (HRT) market in important regions, including the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc. Key regions covered in the report are North America, Europe, Asia-Pacific and Latin America.

The report has been curated after observing and studying various factors that determine regional growth such as economic, environmental, social, technological, and political status of the particular region. Analysts have studied the data of revenue, production, and manufacturers of each region. This section analyses region-wise revenue and volume for the forecast period of 2015 to 2025. These analyses will help the reader to understand the potential worth of investment in a particular region.

Key Strategic Developments:The study also includes the key strategic developments of the Hormone Replacement Therapy (HRT)market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

Key Market Features:The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, market share, CAGR, and gross margin.Analytical Tools: The Hormone Replacement Therapy (HRT) Market report includes the precisely studied and weighed data of the key industry players and their scope in the Hormone Replacement Therapy (HRT) market by means of several analytical tools

Read More Report: http://marketresearchbazaar.com/requestSample/16848

About (Market Research Bazaar):

Market Research Bazaar (MRB)- a part of VRRB Reports LLP is an overall Market Research and consulting organization. We give unparalleled nature of offering to our clients present all around the world crosswise over industry verticals. Market Research Bazaar has aptitude in giving profound jump showcase understanding alongside advertise knowledge to our clients spread across over different endeavours.

Media Contact:

Market Research Bazaar

UK: +442070973908

US: +13156360953

India: +919548234540

Email: [emailprotected]

Website: http://marketresearchbazaar.com/

Blog: http://marketresearchbazaar.com/blogs

Follow this link:
Hormone Replacement Therapy (HRT) MARKET SIZE BY APPLICATION, TYPES, END-USER, REGIONAL ANALYSIS AND FORECAST 2020 TO 2025 - 3rd Watch News

Posted in Hormone Replacement Therapy | Comments Off on Hormone Replacement Therapy (HRT) MARKET SIZE BY APPLICATION, TYPES, END-USER, REGIONAL ANALYSIS AND FORECAST 2020 TO 2025 – 3rd Watch News

Page 32«..1020..31323334..4050..»